Aigen Investment Management LP Acquires New Holdings in MiMedx Group, Inc. (NASDAQ:MDXG)

Aigen Investment Management LP acquired a new stake in shares of MiMedx Group, Inc. (NASDAQ:MDXG) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 14,088 shares of the company’s stock, valued at approximately $83,000.

Several other hedge funds also recently bought and sold shares of MDXG. Harbor Capital Advisors Inc. grew its stake in MiMedx Group by 299.9% during the third quarter. Harbor Capital Advisors Inc. now owns 1,027,738 shares of the company’s stock valued at $6,074,000 after acquiring an additional 770,744 shares in the last quarter. Millennium Management LLC grew its stake in MiMedx Group by 339.9% during the second quarter. Millennium Management LLC now owns 889,446 shares of the company’s stock valued at $6,164,000 after acquiring an additional 687,267 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in MiMedx Group by 47.0% during the second quarter. Dimensional Fund Advisors LP now owns 1,292,822 shares of the company’s stock valued at $8,958,000 after acquiring an additional 413,443 shares in the last quarter. Paradigm Capital Management Inc. NY grew its stake in MiMedx Group by 6.6% during the second quarter. Paradigm Capital Management Inc. NY now owns 4,167,200 shares of the company’s stock valued at $28,879,000 after acquiring an additional 258,700 shares in the last quarter. Finally, Los Angeles Capital Management LLC purchased a new position in MiMedx Group during the second quarter valued at approximately $988,000. Hedge funds and other institutional investors own 79.15% of the company’s stock.

Wall Street Analysts Forecast Growth

MDXG has been the subject of several research analyst reports. StockNews.com lowered shares of MiMedx Group from a “strong-buy” rating to a “buy” rating in a research report on Friday, November 8th. Cantor Fitzgerald reiterated an “overweight” rating and set a $11.00 target price on shares of MiMedx Group in a research report on Thursday, August 1st. Finally, Craig Hallum dropped their target price on shares of MiMedx Group from $14.00 to $12.00 and set a “buy” rating for the company in a research report on Thursday, August 1st. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $12.00.

MiMedx Group Trading Up 0.5 %

Shares of MDXG opened at $9.28 on Monday. The firm has a market cap of $1.36 billion, a price-to-earnings ratio of 16.87 and a beta of 1.94. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.53 and a current ratio of 4.10. MiMedx Group, Inc. has a fifty-two week low of $5.47 and a fifty-two week high of $9.48. The firm has a 50 day moving average price of $6.30 and a 200-day moving average price of $6.77.

MiMedx Group Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.